ISEE News and Press, IVERIC bio Inc. From 05/30/23

2023-05-30 15:02:46 ET Summary Iveric bio, Inc., focused on developing treatments for retinal diseases, has announced its acquisition by Astellas Pharma Inc. Iveric bio, Inc. stock trades at a discount of over 5% for an acquisition that is targeted to close in the third calendar q...

2023-05-23 13:17:29 ET Bayer ( OTCPK:BAYZF ) and Amgen ( AMGN ) were interested in Iveric Bio ( NASDAQ: ISEE ) before it agreed to a $5.9 billion sale to Astellas ( OTCPK:ALPMF ). Iveric ( ISEE ) detailed in a proxy filed on Tuesday that it reached out ...

NEW YORK, NY / ACCESSWIRE / May 5, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Cvent Holding Corp. (NASDAQ:CVT)'s sa...

2023-05-04 12:20:49 ET Summary Apellis Pharmaceuticals, a commercial-stage biopharmaceutical company, is making significant strides with Syfovre, the first and only FDA-approved treatment for geographic atrophy (GA), a condition affecting millions globally. The company's strong fi...

NEW YORK, NY / ACCESSWIRE / May 3, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Iveric bio, Inc. (NASDAQ:ISEE)'s sale...

NEW YORK, NY / ACCESSWIRE / May 2, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Iveric bio, Inc. (NASDAQ:ISEE)'s s...

2023-05-01 16:28:20 ET With earnings season in full swing, biotechnology stocks were volatile today. Apellis Pharmaceuticals' (NASDAQ: APLS) stock, for instance, dipped by as much as 8.5% in early-morning trading Monday before rallying in the afternoon session. Apellis' shar...

2023-05-01 09:12:47 ET Apellis Pharmaceuticals ( NASDAQ: APLS ) stock weakness, down 7.1% in premarket trading, is a buying opportunity after competitor Iveric Bio ( ISEE ) agreed to be sold to Astellas Pharma ( OTCPK:ALPMF ) for $5.9 billion on Sunday, according to ...

2023-05-01 08:52:41 ET Apellis Pharmaceuticals ( NASDAQ: APLS ) stock weakness, down 7.1% in premarket trading, is a buying opportunity after competitor Iveric Bio ( ISEE ) agreed to be sold to Astellas Pharma ( OTCPK:ALPMF ) for $5.9 billion on Sunday, according to ...

2023-05-01 07:16:39 ET Listen on the go! Subscribe to Wall Street Breakfast on Apple Podcasts and Spotify First Republic Bank ( FRC ) is seized, will be sold to JPMorgan. Nornickel ( NILSY ) board recommends no dividend for first time since 20...